Myda Advisors LLC Bei Gene, Ltd. Transaction History

Myda Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $381,550 - $474,150	-2,500 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$152.5 - $216.77 $381,250 - $541,925	2,500 New	2,500 $384,000
Q1 2018 May 10, 2018	SELL	$97.41 - $177.22 $448,086 - $815,212	-4,600 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$79.6 - $114.73 $366,160 - $527,758	4,600	4,600 $450,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Myda Advisors LLC with notifications on news.